{"title": "Evaluaci\u00f3n econ\u00f3mica de la inclusi\u00f3n en el calendario vacunal de 4CMenB (Bexsero\u00ae) en Espa\u00f1a", "author": "Ruiz-Montero; Rafael; Epstein; David; Guzm\u00e1n Herrador; Bernardo; Esp\u00edn Balbino; Jaime", "url": null, "hostname": null, "description": "Introducci\u00f3n Bexsero\u00ae (4CMenB), vacuna contra el meningococo B, fue autorizada en Europa en 2013. En Espa\u00f1a, a pesar de que el meningococo B es la principal causa de enfermedad meningoc\u00f3cica invasiva (EMI), Bexsero\u00ae est\u00e1 recomendada y financiada para pacientes con alto riesgo de EMI pero no de forma sistem\u00e1tica en el calendario vacunal del SNS. Objetivo Evaluar el coste-utilidad, el impacto epidemiol\u00f3gico y los costes totales de la introducci\u00f3n de 4CMenB para una pol\u00edtica vacunal informada en Espa\u00f1a. M\u00e9todo Se adapt\u00f3 para Espa\u00f1a un an\u00e1lisis de coste-utilidad, \u00e1rbol de decisi\u00f3n probabil\u00edstico. Una cohorte de reci\u00e9n nacidos en 2015 fue modelizada con dos posolog\u00edas mediante dos estrategias: vacunaci\u00f3n sistem\u00e1tica con 4CMenB o no vacunaci\u00f3n. Los costes se midieron desde la perspectiva del pagador y los beneficios se calcularon en a\u00f1os de vida ajustados por calidad (AVAC). Se realiz\u00f3 un an\u00e1lisis de Monte Carlo y se consideraron 32 escenarios para valorar la robustez y la incertidumbre de los resultados. Resultados Con la pauta 3+1, la vacunaci\u00f3n sistem\u00e1tica previno el 54% de los casos y de las muertes, y se estim\u00f3 una raz\u00f3n de coste-utilidad incremental (RCUI) de 351.389 \u20ac/AVAC (intervalo de confianza del 95% [IC95%]: 265.193-538.428). La pauta 2+1 previno el 50% de los casos y de las muertes, con una RCUI de 278.556 \u20ac/AVAC (IC95%: 210.285-430.122). Conclusiones Dada la incidencia actual de enfermedad meningoc\u00f3cica invasiva en Espa\u00f1a y la informaci\u00f3n disponible sobre 4CMenB, nuestro modelo indica que la vacunaci\u00f3n sistem\u00e1tica no es coste-efectiva con el actual precio. Solo con un precio de 1,45 \u20ac para la pauta 3+1 o de 3,37 \u20ac para la pauta 2+1 podr\u00eda ser recomendada bas\u00e1ndose en su eficiencia.", "sitename": "Editor responsable del art\u00edculo: Miguel \u00c1ngel Negr\u00edn Hern\u00e1ndez (SESPAS). Publicado por Elsevier Espa\u00f1a, S.L.U.", "date": "2022-04-06", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Por favor, usa este identificador para citar o enlazar este \u00edtem:\nhttp://hdl.handle.net/10668/3526\n|T\u00edtulo :||Evaluaci\u00f3n econ\u00f3mica de la inclusi\u00f3n en el calendario vacunal de 4CMenB (Bexsero\u00ae) en Espa\u00f1a|\nEconomic evaluation of the introduction of 4CMenB (Bexsero\u00ae) in the national vaccine schedule in Spain\n|Autor :|[[Ruiz-Montero,R; Guzm\u00e1n Herrador,B] Unidad de Gesti\u00f3n Cl\u00ednica Interniveles de Prevenci\u00f3n, Promoci\u00f3n y Vigilancia de la Salud, Hospital Universitario Reina Sof\u00eda, C\u00f3rdoba, Espa\u00f1a. [Ruiz-Montero,R; Guzm\u00e1n Herrador,B] Instituto Maim\u00f3nides de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba (Imibic), C\u00f3rdoba, Espa\u00f1a. [Ruiz-Montero,R; Guzm\u00e1n Herrador,B] Facultad de Medicina y Enfermer\u00eda, Universidad de C\u00f3rdoba, C\u00f3rdoba, Espa\u00f1a. [Epstein,D] Facultad de Ciencias Econ\u00f3micas y Empresariales, Universidad de Granada, Granada, Espa\u00f1a. [Esp\u00edn Balbino,J] Escuela Andaluza de Salud P\u00fablica, Granada, Espa\u00f1a. [Esp\u00edn Balbino,J] Instituto de Investigaci\u00f3n Biosanitaria (ibs Granada), Granada, Espa\u00f1a. [Esp\u00edn Balbino,J] CIBER de Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP), Espa\u00f1a.](/browse?type=author&value=%5BRuiz-Montero%2CR%3B+Guzm%C3%A1n+Herrador%2CB%5D+Unidad+de+Gesti%C3%B3n+Cl%C3%ADnica+Interniveles+de+Prevenci%C3%B3n%2C+Promoci%C3%B3n+y+Vigilancia+de+la+Salud%2C+Hospital+Universitario+Reina+Sof%C3%ADa%2C+C%C3%B3rdoba%2C+Espa%C3%B1a.+%5BRuiz-Montero%2CR%3B+Guzm%C3%A1n+Herrador%2CB%5D+Instituto+Maim%C3%B3nides+de+Investigaci%C3%B3n+Biom%C3%A9dica+de+C%C3%B3rdoba+%28Imibic%29%2C+C%C3%B3rdoba%2C+Espa%C3%B1a.+%5BRuiz-Montero%2CR%3B+Guzm%C3%A1n+Herrador%2CB%5D+Facultad+de+Medicina+y+Enfermer%C3%ADa%2C+Universidad+de+C%C3%B3rdoba%2C+C%C3%B3rdoba%2C+Espa%C3%B1a.+%5BEpstein%2CD%5D+Facultad+de+Ciencias+Econ%C3%B3micas+y+Empresariales%2C+Universidad+de+Granada%2C+Granada%2C+Espa%C3%B1a.+%5BEsp%C3%ADn+Balbino%2CJ%5D+Escuela+Andaluza+de+Salud+P%C3%BAblica%2C+Granada%2C+Espa%C3%B1a.+%5BEsp%C3%ADn+Balbino%2CJ%5D+Instituto+de+Investigaci%C3%B3n+Biosanitaria+%28ibs+Granada%29%2C+Granada%2C+Espa%C3%B1a.+%5BEsp%C3%ADn+Balbino%2CJ%5D+CIBER+de+Epidemiolog%C3%ADa+y+Salud+P%C3%BAblica+%28CIBERESP%29%2C+Espa%C3%B1a.)\nMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans\nMedical Subject Headings::Persons::Persons::Age Groups::Infant\nMedical Subject Headings::Geographical Locations::Geographic Locations::Europe::Spain\nMedical Subject Headings::Diseases::Bacterial Infections and Mycoses::Bacterial Infections::Gram-Negative Bacterial Infections::Neisseriaceae Infections::Meningococcal Infections\nMedical Subject Headings::Chemicals and Drugs::Complex Mixtures::Biological Products::Vaccines::Bacterial Vaccines::Meningococcal Vaccines\nMedical Subject Headings::Health Care::Health Care Facilities, Manpower, and Services::Health Services::Community Health Services::Preventive Health Services::Immunization Programs::Mass Vaccination\nMedical Subject Headings::Organisms::Bacteria::Gram-Negative Bacteria::Gram-Negative Aerobic Bacteria::Gram-Negative Aerobic Rods and Cocci::Neisseriaceae::Neisseria::Neisseria meningitidis::Neisseria meningitidis, Serogroup B\nMedical Subject Headings::Health Care::Health Care Facilities, Manpower, and Services::Health Services::Community Health Services::Preventive Health Services::Immunization Programs\nIntroduction Bexsero\u00ae (4CMenB), meningococcal B vaccine, was licensed in Europe in 2013. In Spain, despite MenB being the most frequent cause of invasive meningococcal disease (IMD), Bexsero\u00ae is recommended and financed for patients at increased risk of IMD but is not financed by the NHS in the routine vaccination schedule. Objective to evaluate the cost-utility, epidemiological impact, and total costs of the introduction of 4CMenB into the vaccination schedule to help inform vaccine policy in Spain. Method We adapted a cost-utility analysis, a probabilistic decision-tree, to Spain. A cohort of new-born infants in 2015 was modelled with two dosages, using two different strategies: routine vaccination schedule with 4CMenB and non-vaccination. Costs were measured from a payer perspective and benefits were calculated in quality-adjusted life years (QALYs). A Monte Carlo analysis and 32 scenarios were performed to assess the robustness and the uncertainty of our results. Results With the 3+1 dosage, routine vaccination prevented 54% of cases and deaths and an incremental cost-utility ratio (ICUR) of 351.389 \u20ac/QALY (95% confidence interval [95%CI]: 265,193-538,428) was estimated. The 2+1 dosage prevented 50% of cases and deaths, with an ICUR of 278.556 \u20ac/QALY (95%CI: 210,285-430,122). Conclusions Given the current incidence of invasive meningococcal disease in Spain and the information available from 4CMenB, our model shows that routine vaccination is not cost-effective at the current price. Only with a vaccine price of 1.45 \u20ac for the 3+1 schedule or 3.37 \u20ac for the 2+1 schedule could it be recommended based on efficiency criteria.\n[http://hdl.handle.net/10668/3526](http://hdl.handle.net/10668/3526) [https://www.gacetasanitaria.org/es-evaluacion-economica-inclusion-el-calendario-articulo-S0213911119302171](https://www.gacetasanitaria.org/es-evaluacion-economica-inclusion-el-calendario-articulo-S0213911119302171) [10.1016/j.gaceta.2019.08.007](http://dx.doi.org/10.1016/j.gaceta.2019.08.007) [Escuela Andaluza de Salud P\u00fablica](/handle/10668/22666) [Instituto de Investigaci\u00f3n Biosanitaria de Granada (ibsGRANADA)](/handle/10668/22652) [Instituto Maim\u00f3nides de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba (IMIBIC)](/handle/10668/22653) [SAS - Hospital Universitario Reina Sof\u00eda](/handle/10668/22732)\nFicheros en este \u00edtem:\n|Fichero||Descripci\u00f3n||Tama\u00f1o||Formato|\n[Visualizar/Abrir](/bitstream/10668/3526/1/RuizMontero_EvaluacionEconomica.pdf)\nEste \u00edtem est\u00e1 protegido por copyright original\nEste \u00edtem est\u00e1 sujeto a una licencia Creative Commons\n[Licencia Creative Commons ](http://creativecommons.org/licenses/by-nc-nd/4.0/)", "language": null, "image": null, "pagetype": null, "links": ["#content", "/", "/", "#", "/community-list", "/browse?type=dateissued", "/browse?type=author", "/browse?type=title", "/browse?type=subject", "#", "/about/about_es.jsp", "/about/deposit-guide_es.jsp", "/about/author-rights_es.jsp", "/externalSubmission/index.jsp", "/help/index_es.jsp", "#", "http://www.repositoriosalud.es/handle/10668/3526?locale=es", "http://www.repositoriosalud.es/handle/10668/3526?locale=en", "#", "/mydspace", "/subscribe", "/profile", "/", "/handle/10668/22641", "/handle/10668/22644", "/handle/10668/22732", "/browse?type=author&value=Ruiz-Montero%2C+Rafael", "/browse?type=author&value=Epstein%2C+David", "/browse?type=author&value=Guzm%C3%A1n+Herrador%2C+Bernardo", "/browse?type=author&value=Esp%C3%ADn+Balbino%2C+Jaime", "/browse?type=author&value=%5BRuiz-Montero%2CR%3B+Guzm%C3%A1n+Herrador%2CB%5D+Unidad+de+Gesti%C3%B3n+Cl%C3%ADnica+Interniveles+de+Prevenci%C3%B3n%2C+Promoci%C3%B3n+y+Vigilancia+de+la+Salud%2C+Hospital+Universitario+Reina+Sof%C3%ADa%2C+C%C3%B3rdoba%2C+Espa%C3%B1a.+%5BRuiz-Montero%2CR%3B+Guzm%C3%A1n+Herrador%2CB%5D+Instituto+Maim%C3%B3nides+de+Investigaci%C3%B3n+Biom%C3%A9dica+de+C%C3%B3rdoba+%28Imibic%29%2C+C%C3%B3rdoba%2C+Espa%C3%B1a.+%5BRuiz-Montero%2CR%3B+Guzm%C3%A1n+Herrador%2CB%5D+Facultad+de+Medicina+y+Enfermer%C3%ADa%2C+Universidad+de+C%C3%B3rdoba%2C+C%C3%B3rdoba%2C+Espa%C3%B1a.+%5BEpstein%2CD%5D+Facultad+de+Ciencias+Econ%C3%B3micas+y+Empresariales%2C+Universidad+de+Granada%2C+Granada%2C+Espa%C3%B1a.+%5BEsp%C3%ADn+Balbino%2CJ%5D+Escuela+Andaluza+de+Salud+P%C3%BAblica%2C+Granada%2C+Espa%C3%B1a.+%5BEsp%C3%ADn+Balbino%2CJ%5D+Instituto+de+Investigaci%C3%B3n+Biosanitaria+%28ibs+Granada%29%2C+Granada%2C+Espa%C3%B1a.+%5BEsp%C3%ADn+Balbino%2CJ%5D+CIBER+de+Epidemiolog%C3%ADa+y+Salud+P%C3%BAblica+%28CIBERESP%29%2C+Espa%C3%B1a.", "http://hdl.handle.net/10668/3526", "https://www.gacetasanitaria.org/es-evaluacion-economica-inclusion-el-calendario-articulo-S0213911119302171", "http://dx.doi.org/10.1016/j.gaceta.2019.08.007", "/handle/10668/22666", "/handle/10668/22652", "/handle/10668/22653", "/handle/10668/22732", "/bitstream/10668/3526/1/RuizMontero_EvaluacionEconomica.pdf", "/bitstream/10668/3526/1/RuizMontero_EvaluacionEconomica.pdf", "/retrieve/493527f7-48e3-4d66-9217-ddfdccc0d46b/license.txt", "/handle/10668/3526?mode=full", "/suggest?handle=10668/3526", "/handle/10668/3526/statistics", "http://creativecommons.org/licenses/by-nc-nd/4.0/", "http://creativecommons.org/licenses/by-nc-nd/4.0/", "http://www.cineca.it", "http://www.dspace.org/", "https://www.bvsspa.es/", "/feedback", "/about/author-rights_es.jsp", "/about/privacyPolicy_es.jsp", "/htmlmap"]}